These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. Domont J; Massard C; Lassau N; Armand JP; Le Cesne A; Soria JC Invest New Drugs; 2010 Apr; 28(2):199-202. PubMed ID: 19352594 [No Abstract] [Full Text] [Related]
12. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Ozao-Choy J; Ma G; Kao J; Wang GX; Meseck M; Sung M; Schwartz M; Divino CM; Pan PY; Chen SH Cancer Res; 2009 Mar; 69(6):2514-22. PubMed ID: 19276342 [TBL] [Abstract][Full Text] [Related]
13. Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics. Finke JH; Rayman PA; Ko JS; Bradley JM; Gendler SJ; Cohen PA Cancer J; 2013; 19(4):353-64. PubMed ID: 23867518 [TBL] [Abstract][Full Text] [Related]
14. [Circulating Myeloid Suppressor Cells and Their Role in Tumour Immunology]. Pilatova K; Budinská E; Bensciková B; Nenutil R; Šefr R; Fedorová L; Hanáková B; Brychtová V; Zdražilová Dubská L Klin Onkol; 2017; 30(Supplementum1):166-169. PubMed ID: 28471197 [TBL] [Abstract][Full Text] [Related]
15. The effect of anti-angiogenic drugs on regulatory T cells in the tumor microenvironment. Hu C; Jiang X Biomed Pharmacother; 2017 Apr; 88():134-137. PubMed ID: 28103506 [TBL] [Abstract][Full Text] [Related]
17. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy. Chen HM; Ma G; Gildener-Leapman N; Eisenstein S; Coakley BA; Ozao J; Mandeli J; Divino C; Schwartz M; Sung M; Ferris R; Kao J; Wang LH; Pan PY; Ko EC; Chen SH Clin Cancer Res; 2015 Sep; 21(18):4073-4085. PubMed ID: 25922428 [TBL] [Abstract][Full Text] [Related]
18. Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib. DePrimo SE; Bello C Ann Oncol; 2007 Sep; 18 Suppl 10():x11-9. PubMed ID: 17761718 [TBL] [Abstract][Full Text] [Related]
19. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model. Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553 [TBL] [Abstract][Full Text] [Related]